Antibody-drug conjugates (ADCs) are gaining traction in APAC, marked by significant investments and collaborations, particularly from Chinese companies, signaling strong potential in targeted cancer therapies.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.